BeOne Medicines AG (ONC)
| Market Cap | 33.04B |
| Revenue (ttm) | 5.34B |
| Net Income (ttm) | 286.93M |
| Shares Out | 110.90M |
| EPS (ttm) | 2.47 |
| PE Ratio | 121.01 |
| Forward PE | 52.71 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 129,856 |
| Open | 300.20 |
| Previous Close | 298.90 |
| Day's Range | 297.00 - 301.05 |
| 52-Week Range | 218.31 - 385.22 |
| Beta | 0.54 |
| Analysts | Strong Buy |
| Price Target | 380.45 (+27.69%) |
| Earnings Date | May 6, 2026 |
About ONC
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients w... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for ONC stock is "Strong Buy." The 12-month stock price target is $380.45, which is an increase of 27.69% from the latest price.
News
BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its first quarter 2026 financial results on We...
Baker Bros. Advisors LP's Strategic Acquisition of BeOne Medicines Ltd Shares
Baker Bros. Advisors LP's Strategic Acquisition of BeOne Medicines Ltd Shares
BeiGene Acquires Exclusive Rights for Fizepizumab in Greater China
BeiGene Acquires Exclusive Rights for Fizepizumab in Greater China
BeiGene (ONC) Prepares for Q1 Earnings Announcement with Strong Track Record
BeiGene (ONC) Prepares for Q1 Earnings Announcement with Strong Track Record
BeOne Medicines (ONC) Receives Conditional Approval for Lung Cancer Treatment
BeOne Medicines (ONC) Receives Conditional Approval for Lung Cancer Treatment
If You Invested $100 In BeOne Medicines Stock 10 Years Ago, You Would Have This Much Today
BeOne Medicines (NASDAQ: ONC) has outperformed the market over the past 10 years by 13.53% on an annualized basis producing an average annual return of 25.92%. Currently, BeOne Medicines has a market...
ONC: Jefferies Downgrades BeOne Medicines to Hold, Lowers Price Target | ONC Stock News
ONC: Jefferies Downgrades BeOne Medicines to Hold, Lowers Price Target | ONC Stock News
BeOne Medicines Ltd (ONC) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Expansion
BeOne Medicines Ltd (ONC) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Expansion
Q4 2025 BeOne Medicines AG Earnings Call Transcript
Q4 2025 BeOne Medicines AG Earnings Call Transcript
BeOne Medicines is Now Oversold (ONC)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
BeOne Medicines AG at TD Cowen Healthcare Conference Transcript
BeOne Medicines AG at TD Cowen Healthcare Conference Transcript
BeOne Medicines (ONC) Shares Cross Below 200 DMA
In trading on Monday, shares of BeOne Medicines Ltd (Symbol: ONC) crossed below their 200 day moving average of $309.82, changing hands as low as $304.62 per share. BeOne Medicines Ltd shares are curr...
BeOne Medicines AG Transcript: TD Cowen 46th Annual Health Care Conference
Revenue guidance for 2026 is $6.2–$6.4 billion, driven by global growth and strong product performance. Multiple pipeline assets are advancing, with key data readouts and registrational studies planned for 2024–2026. Hematology assets show strong differentiation and market expansion potential.
BeOne Medicines AG Earnings Call Transcript: Q4 2025
Delivered strong 2025 results with 49% BRUKINSA revenue growth, GAAP profitability, and robust cash flow. 2026 guidance projects $6.2–$6.4 billion revenue, driven by continued BTK leadership and new launches. R&D pipeline advanced with multiple Phase III studies and global approvals.
BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates fr...
BeOne Medicines to Present at Upcoming Investor Conferences
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in fires...
Prediction: These 3 Stocks Will Crush the Market in 2026
Alphabet is poised to convert much of its record Google Cloud backlog into recognized revenue this year. BeOne Medicines could soon win approval for a powerhouse blood cancer therapy.
BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its fourth quarter and full year 2025 financia...
3 Stocks to Buy in February
Amazon's earnings should continue to grow robustly. BeOne Medicines has two potential catalysts on the way soon.
BeOne Medicines AG Transcript: 44th Annual J.P. Morgan Healthcare Conference
Major advances in CLL therapy were highlighted, with BRUKINSA setting new efficacy and safety standards and new combinations like BRUKINSA plus sonrotoclax poised to redefine fixed-duration treatment. Operational excellence and a robust pipeline support strong financials and future growth.
BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will outline the pillars of its growing global oncology le...
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-...
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P...
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration...
Senhwa Biosciences and BeOne Medicines Announces a Clinical Supply Agreement to Address the Challenge of Cold Tumors
TAIPEI and SAN DIEGO , Dec. 10, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company developing first-in-class therapies for difficult-to-treat cancer...